Financials

	2023	2024
Net sales	450K 395K 373K 340K 636K 43.09M 640K 4.46M 1.73M 22.02M 1.69M 1.65M 70.76M	536K 471K 445K 405K 758K 51.41M 764K 5.32M 2.06M 26.26M 2.01M 1.97M 84.41M
Net income	-4.62M -4.05M -3.83M -3.49M -6.53M -443M -6.58M -45.81M -17.74M -226M -17.34M -16.97M -727M	-5.02M -4.4M -4.16M -3.79M -7.09M -481M -7.14M -49.75M -19.27M -246M -18.83M -18.43M -789M
Net Debt	-3.16M -2.77M -2.62M -2.38M -4.46M -303M -4.5M -31.31M -12.13M -155M -11.85M -11.6M -497M	-2.14M -1.88M -1.77M -1.61M -3.02M -205M -3.04M -21.2M -8.21M -105M -8.02M -7.85M -336M

* Estimated data More financial data

Company Profile

Lipella Pharmaceuticals Inc. was a clinical-stage biotechnology company. The Company is no longer in operation and does not have any business activities.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/09/26	$0.000500	0.00%	1,001

Delayed Quote OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 16:30:05 24/09/2026 +03			5-day change	1st Jan Change
0.000500 ^USD	0.00%		0.00%	-99.72%

07-15	An undisclosed buyer agreed to acquire Substantially all of the assets of Lipella Pharmaceuticals Inc from Lipella Pharmaceuticals Inc. for $3.4 million.	CI
03-31	Lipella Pharmaceuticals Inc. files voluntary petitions for relief under Chapter 11	RE

Market Cap	832K 730K 689K 628K 1.18M 79.72M 1.18M 8.25M 3.19M 40.73M 3.12M 3.06M 131M	P/E 2023	-1.32x	P/E 2024	-0.64x
Enterprise Value	-1.31M -1.15M -1.08M -986K -1.85M -125M -1.86M -12.95M -5.01M -63.92M -4.9M -4.8M -205M	EV / Sales 2023	6.14x	EV / Sales 2024	2.89x
Free-Float	93.69%	Yield 2023 *	-	Yield 2024	-

07-15	An undisclosed buyer agreed to acquire Substantially all of the assets of Lipella Pharmaceuticals Inc from Lipella Pharmaceuticals Inc. for $3.4 million.	CI
03-31	Lipella Pharmaceuticals Inc. files voluntary petitions for relief under Chapter 11	RE
03-30	Lipella Pharmaceuticals Inc. Filed for Bankruptcy	CI
02-05	Lipella Pharmaceuticals Inc. Announces Resignation of Director Lori A. Birder, Effective February 3, 2026	CI
11-15	Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10/10/25	Lipella Pharmaceuticals Inc. Announces Retirement of Michael Chancellor as Chief Medical Officer and Member of the Board of Directors, Effective December 4, 2025	CI
18/09/25	Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus	CI
18/09/25	Lipella Pharmaceuticals announces positive final results from Phase 2a study of LP-10 in oral lichen planus	RE
15/08/25	Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
24/06/25	Lipella Pharmaceuticals Inc.(NasdaqCM:LIPO) dropped from S&P TMI Index	CI
19/06/25	Lipella Pharmaceuticals Inc.(OTCPK:LIPO) dropped from NASDAQ Composite Index	CI
04/06/25	Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development	CI
15/05/25	Lipella Pharmaceuticals to Present Phase 2A Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting	CI

11/02/25	Top Midday Gainers	MT
09/04/24	Maxim Initiates Lipella Pharmaceuticals at Buy Rating With $2 Price Target	MT

Lipella Pharmaceuticals Inc. Stock

Stocks

LIPO

US53630L2097

Biotechnology & Medical Research

Valuation: Lipella Pharmaceuticals Inc.

Chart: Lipella Pharmaceuticals Inc.

Latest news: Lipella Pharmaceuticals Inc.

Analysts' recommendations: Lipella Pharmaceuticals Inc.

Press Releases: Lipella Pharmaceuticals Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Lipella Pharmaceuticals Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

18/09/25	Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus	AQ
15/09/25	Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus	PR
25/06/25	Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting	AQ
20/06/25	Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market	AQ
17/06/25	Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology	AQ

Current month	-98.47%
1 month	+25.00%
3 months	-99.44%
6 months	-99.67%
Current year	-99.72%

1 week	0		0
1 month	0		0
Current year	0		0.32
1 year	0		0.64
3 years	0		21.68
5 years	0		61.76
10 years	0		61.76

Manager	Title	Age	Since
Jonathan Kaufman CEO	Chief Executive Officer	60	01/01/2005
Douglas Johnston DFI	Director of Finance/CFO	42	01/10/2021
Janet Okonski CTO	Chief Tech/Sci/R&D Officer	-	01/08/2021

Director	Title	Age	Since
Jonathan Kaufman CHM	Chairman	60	01/01/2005
Byong Kim BRD	Director/Board Member	55	01/03/2022
Ryan Pruchnic BRD	Director/Board Member	53	01/09/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/3/25 A	Jonathan Kaufman	Others	Chief Executive Officer	695,776	27.2981%
3/13/25 A	Jonathan Kaufman	Others	Chief Executive Officer	14,386	0.5644%
3/10/25 A	Jonathan Kaufman	Others	Chief Executive Officer	28,924	1.1348%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LIPELLA PHARMACEUTICALS INC.	0.00%	0.00%	-99.92%	-100.00%	2.31K
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+51.24%	+99.26%	72.26B
ARGENX SE	+1.25%	-3.01%	+40.12%	+77.12%	60.24B
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+32.50%	+21.28%	27.73B
INSMED INCORPORATED	-3.06%	-1.81%	-13.10%	+357.06%	25.74B
BIONTECH SE	-0.75%	+2.56%	+0.45%	-4.46%	24.75B
GENMAB A/S	+0.40%	+0.75%	+22.91%	-9.68%	20.74B
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+146.86%	+314.52%	15.06B
EXELIXIS, INC.	+0.36%	-0.34%	+50.32%	+166.42%	14.42B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-8.07%	+499.10%	14.23B
Average	-0.45%	+0.40%	+22.33%	+142.06%	27.52B
Weighted average by Cap.	-0.77%	+0.31%	+36.31%	+129.11%